Literature DB >> 11063277

Hospital-based policies for prevention perinatal Group B streptococcal disease--United States, 1999.

.   

Abstract

Group B streptococcus (GBS) is the leading cause of sepsis, meningitis, and pneumonia in newborns in the United States (1). Because intrapartum prophylactic antibiotics reduce mother-to-child GBS transmission (2), in 1996, CDC, the American College of Obstetricians and Gynecologists, and the American Academy of Pediatrics recommended that hospitals adopt formal GBS prevention policies (2-4). From 1994 to 1997, the proportion of hospitals with formal intrapartum GBS prevention policies increased from 39% to 59% (5,6); hospitals that implemented policies reported less GBS disease among neonates (7). In 1999, CDC's Active Bacterial Core Surveillance (ABCs) system surveyed hospitals in eight states about their GBS prevention policies. This report summarizes the results of that analysis and indicates that in 1999, the proportion of hospitals with formal policies had not changed since 1997; however, a higher proportion of hospitals have implemented measures to improve policy compliance.

Entities:  

Mesh:

Year:  2000        PMID: 11063277

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  2 in total

1.  Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections.

Authors:  Anne Schuchat; Aaron Roome; Elizabeth R Zell; Heather Linardos; Sara Zywicki; Katherine L O'Brien
Journal:  Matern Child Health J       Date:  2002-06

2.  Institutional prevention policies and rates of Group B Streptococcus infection among HIV-infected pregnant women and their infants in Latin America.

Authors:  Esaú Joao; Maria I Gouvea; Laura Freimanis-Hance; Rachel A Cohen; Jennifer S Read; Victor Melo; Geraldo Duarte; Silvina Ivalo; Daisy M Machado; Jose Pilotto; George K Siberry
Journal:  Int J Gynaecol Obstet       Date:  2012-12-20       Impact factor: 3.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.